Finally, the last clinically important member of prostate cancer biomarkers is the prostate-specific membrane antigen (PSMA, N-acetylated-α-linked acidic dipeptidase I or glutamate carboxypeptidase II), which is a membrane-bound glycoprotein heavily overexpressed in PCa, thus being extensively studied and used in PCa theranostics. This evidence concerns the gene FOLH1 and prostate cancer.